An increased risk of developing adrenal insufficiency was observed in younger patients (OR, 0.84; 95% CI, 0.76-0.92; P < .01), male patients (OR, 0.81; 95% CI, 0.66-0.99; P = .04), and those receiving combination therapy of anti-PD-1 and anti-CTLA-4 (compared with anti-PD-1 monotherapy, OR, 3.35; 95% CI, 2.50-4.50; P < .01). The gene discussed is CTLA4; the disease is Adrenal insufficiency.